Bris­tol My­ers re­in­forces neu­ro­science deals; Io­vance prices $150M pub­lic of­fer­ing

Bris­tol My­ers Squibb, a big phar­ma hard­ly syn­ony­mous with neu­ro­science drugs, is beef­ing up its work with two Eu­ro­pean biotechs in Alzheimer’s and undis­closed neu­rode­gen­er­a­tive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER